Tonix Pharmaceuticals Holding (TNXP) 10-Q2024 Q1 Quarterly report

Filed: 13 May 24, 4:51pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Bad

New words: accelerated, acknowledgement, affirmative, anniversary, bear, brokerage, build, building, capacity, Cayman, CBRE, Charter, classification, covenant, criteria, default, denominator, disaggregated, DLOM, earliest, easily, Ellen, embedded, estate, exposure, fewer, firm, full, gain, Guaranty, Hedging, hereto, identical, impracticable, inaccuracy, insolvency, instrument, insufficient, invalidity, iv, JGB, lack, lender, loan, LP, margin, merger, multiple, NDA, nominal, North, oversee, partner, physical, pivotal, Port, prepayment, prime, prioritization, priority, profit, reaction, real, receipt, reclassification, reclassified, recoverable, regularly, repayment, residual, scheduled, secured, security, sequencing, short, successful, Tonmya, tradename, unchanged, undiscounted, unissued, unpaid, voluntary

Removed: academic, addiction, Alberta, buildout, cast, chronic, composed, conversion, convert, converted, cover, Curia, cyclobenzaprine, deduction, digit, disbursed, discovering, disorder, emerging, exchanged, excluding, feature, fractional, HCl, identifying, initiated, intranasal, lapse, lead, live, mandatory, mezzanine, milestone, mirrored, mpox, neurologic, obesity, OID, Orphan, oxytocin, pain, par, potentiated, pox, prohibited, psychiatric, recombinant, redeem, redeemable, redeemed, redeeming, redemption, removed, removing, representing, retroactively, separation, smallpox, study, sublingual, Subtopic, syndrome, tablet, topline, unregistered, voted, voting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TNXP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q

Exhibit 32.01

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp. on Form 10-Q for the fiscal quarter ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ SETH LEDERMAN
Date: May 13, 2024		Name: Seth Lederman
		Title: Chief Executive Officer

I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp. on Form 10-Q for the fiscal quarter ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ BRADLEY SAENGER
Date: May 13, 2024		Name: Bradley Saenger
		Title: Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.